Heated tobacco products (HTPs) are marketed as lower-risk alternatives to conventional cigarettes; however, their toxicological impacts remain insufficiently characterized. This study evaluated the effects of HTP emissions on gene expression and mitochondrial function in comparison with conventional cigarettes. Whole cigarette smoke condensates (WCSCs), comprising both gas and particulate phases, were prepared from three commercially available HTPs and from 3R4F reference cigarettes. Human lung epithelial BEAS-2B cells were exposed to WCSCs at 3 μg nicotine/mL for 24 h, followed by transcriptome profiling using RNA sequencing. Principal component analysis demonstrated that HTP-WCSCs induced weaker gene expression changes than 3R4F-WCSC, with only modest variation among HTPs. Gene set enrichment analysis revealed that both HTP- and 3R4F-WCSCs significantly downregulated oxidative phosphorylation (OXPHOS)–related pathways, indicating potential mitochondrial impairment. Functional assays confirmed that both exposures elevated mitochondrial reactive oxygen species (ROS), while mitochondrial morphology, ATP production, membrane potential, and cytosolic ROS were largely unaffected. Collectively, these results show that although HTP emissions elicit weaker transcriptomic perturbations than conventional cigarette emissions, both converge on mitochondrial targets by suppressing OXPHOS gene expression and increasing mitochondrial ROS. Mitochondrial dysfunction may therefore represent a common mechanism underlying tobacco product toxicity.

Small-molecule immunomodulators have become important components of modern immunotherapy by targeting immune checkpoints, cytokine signaling pathways, metabolic enzymes, and intracellular kinases. Despite pharmacological rationale, many of these agents underperform clinically due to unfavorable physicochemical properties, rapid systemic clearance, limited target accumulation, and dose-limiting toxicities, reflecting inadequate exposure control rather than a lack of target validity. Polymeric micelles, formed through the self-assembly of amphiphilic block copolymers, offer a versatile delivery platform to address these challenges by enhancing solubility, modulating pharmacokinetics, enabling stimuli-responsive release, and facilitating targeted or synchronized co-delivery. In this review, we classify representative small-molecule immunomodulators according to their immunological targets and examine the delivery constraints that shape their therapeutic performance. We then discuss design principles of polymeric micelle systems, including solubilization-driven formulations, microenvironment-responsive architectures, spatial targeting strategies, and co-delivery approaches that align cytotoxic and immunomodulatory mechanisms. Attention is given to the distinction between direct immunomodulators and cytotoxic agents that induce immunogenic cell death, highlighting how micelle-based delivery can enhance efficacy through improved exposure control. By integrating immunopharmacology with formulation science, this review outlines how polymeric micelles may advance the efficacy and safety of small-molecule immunomodulators and identifies key considerations for future translational development.